CCL2 and neoplasm: Simvastatin could decrease CCL3 expression from cancer cells and ICAM-1, VCAM1, IL-6, and CCL2 expression from CaMSCs, disrupting the crosstalk of the cancer cells and tumor microenvironments (TME) and inhibiting tumor progression [44].